Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
| Autor: | Kaymaz, Serdar, Karasu, Uğur, Çobankara, Veli, Alkan, Hakan, Ulutas, F. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
anti-tumor necrosis factor
hydroxychloroquine oseltamivir mortality rate Review virus pneumonia blood culture coronavirus disease 2019 immunoglobulin G male adalimumab ankylosing spondylitis antiviral therapy malaise middle aged x-ray computed tomography case report follow up Severe acute respiratory syndrome coronavirus 2 human golimumab arthralgia tumor necrosis factor inhibitor coughing thorax radiography azithromycin loss of appetite clinical article emergency ward C reactive protein adult disease course ferritin lactate dehydrogenase home quarantine clinical feature sore throat hospital admission female priority journal real time polymerase chain reaction laboratory test dysgeusia infliximab headache |
| Popis: | The mortality rate for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is increasing worldwide with each passing day. The risk factors for mortality include advanced age and comorbidities. It is still uncertain whether biological agents pose a risk for the progression of SARS-CoV-2. Although there are studies suggesting the use of biological agents in the literature, there are also studies suggesting the discontinuation of biological agents during SARS-CoV-2. In this study, we aimed to determine whether anti-tumor necrosis factor (anti-TNF-α agents) therapy, which is one of the biological agents commonly used in rheumatology clinics, has an effect on the clinical course of SARS-CoV-2 infection, and to review the literature. We searched the MEDLINE/PubMed and SCOPUS databases until the date of August 15, 2020, using the following keywords: SARS-CoV-2 and anti-TNF-α agents. We reviewed abstracts and retrieved the relevant articles. We reported the clinical manifestation and disease course of SARS-CoV-2 pneumonia in three patients with ankylosing spondylitis who were receiving anti-TNF-α agents. All patients in our case series had a mild course similar to the most cases reported in the literature. © 2020 Indian Journal of Rheumatology | Published by Wolters Kluwer - Medknow. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|